Claims for Patent: 8,076,362

Summary for Patent: 8,076,362

Title:	Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Abstract:	The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.
Inventor(s):	Portmann; Robert (Pratteln, CH), Hofmeier; Urs Christoph (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	12/767,003
Patent Claims:	1. A solid dosage form for administration comprising an amount ranging from 20 mg to less than 500 mg of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and a solid pharmaceutically-acceptable carrier, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern. 2. The dosage form of claim 1, wherein dosage is in the form of a tablet. 3. The dosage form of claim 1, wherein the amount ranges from 200 to 400 mg. 4. The dosage form of claim 1, further comprising one or more excipients. 5. The dosage form of claim 1, wherein the amount of crystal modification A ranges from approximately 100 mg to 400 mg. 6. The dosage form of claim 1, wherein dosage is in the form of a solid for oral administration. 7. The solid dosage form of claim 1, further comprising a film-coat. 8. The solid dosage form of claim 1, wherein the amount of crystal modification A comprises a dosage unit comprising 200 mg. 9. The solid dosage form of claim 1, wherein the amount of crystal modification A comprises a dosage unit comprising 400 mg. 10. A tablet for oral administration comprising a therapeutically-effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and microcrystalline cellulose wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern. 11. The tablet of claim 10, having a dosage unit of crystal modification A ranging from 200 mg to 400 mg. 12. A tablet for oral administration comprising a therapeutically-effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, a pharmaceutically-acceptable carrier, and a film coat, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG. and 2.81 .ANG., determined by means of an X-ray powder pattern. 13. The tablet of claim 12, having a dosage unit of crystal modification A ranging from 20 mg to less than 500 mg. 14. The tablet of claim 12, having a dosage unit of crystal modification A ranging from 200 mg to 400 mg. 15. The tablet of claim 12, having a dosage unit of crystal modification A comprising 200 mg. 16. The tablet of claim 12, having a dosage unit of crystal modification A comprising 400 mg. 17. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises microcrystalline cellulose. 18. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises sodium carboxymethylcellulose. 19. The tablet of claim 12, wherein the film coat comprises hydroxypropylmethylcellulose. 20. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises microcrystalline cellulose and the film-coat comprises hydroxypropylmethylcellulose. 21. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises sodium carboxymethylcellulose and the film-coat comprises hydroxypropylmethylcellulose.